

## Seeking Novel Oral or Injectable Therapeutics to Treat Obesity

A world-leading health company is seeking **novel therapeutics for obesity, with safety and efficacy data, preferably in canine models**. Approaches should help manage obesity and reduce body condition score, with greater efficacy than diet and/or exercise alone. Our client aims to bring a novel treatment to market within 3-5 years.



Approaches should allow for **oral or injectable delivery, ideally with daily (oral) or monthly (injectable) dosing**. Our client is seeking therapeutics with strong safety profile, with minimal side-effects (i.e. no gastrointestinal distress, hypoglycaemia or injection site reactions). Ideal efficacy data would demonstrate at least 10% loss of body weight within 3 months.

### Approaches of Interest:

- Any therapeutic targets and mechanisms of action relevant to obesity are of interest, including but not limited to GLP-1, GIP, leptin and amylin
- All modalities are of interest, however small molecule, peptide and antibody approaches are preferred
- Approaches that target common obesity comorbidities via pathways shared with obesity are also of interest (e.g. type 2 diabetes, cardiovascular)

### Out of Scope:

- Dietary, behavioural or exercise interventions
- Natural products, nutraceuticals or approaches targeting the microbiome e.g. probiotics
- Any opportunities in development for over-the-counter use

### Developmental Stages of Interest:

- Opportunities should have *in vivo* validation, preferably canine data
- Earlier stage opportunities with novel mechanisms of action and/or pathways to target obesity may also be considered





### Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

### Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Licensing of assets with a timeline to bring to market within 3-5 years is preferred.

## Opportunities sought

-  Biotech assets
-  Spinout companies
-  Research projects
-  Technologies

## Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **5th February 2025 - 11:59 pm GMT**

### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)